Evidence map›Paper›PMID 42225919›Full record

ArticleScientific reports2026

Co-overexpression of ELOVL2 and ELOVL5 promotes clear cell renal cell carcinoma progression through LIMK1-mediated cytoskeletal reorganization.

Shotaro Sakka, Satoshi Nitta, Shuya Kandori, Reo Takahashi, Shuhei Suzuki, Kazuki Hamada, Kozaburo Tanuma, Masanobu Shiga, Yoshiyuki Nagumo, Hiromitsu Negoro and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Shotaro SakkaDepartment of Urology, Institute of Medicine, University of Tsukuba, 1-1-1 Tennodai, Tsukuba, 305-8575, Ibaraki, Japan.
Satoshi NittaDepartment of Urology, Institute of Medicine, University of Tsukuba, 1-1-1 Tennodai, Tsukuba, 305-8575, Ibaraki, Japan.
Shuya KandoriDepartment of Urology, Institute of Medicine, University of Tsukuba, 1-1-1 Tennodai, Tsukuba, 305-8575, Ibaraki, Japan. shuya79@md.tsukuba.ac.jp.
Reo TakahashiDepartment of Urology, Institute of Medicine, University of Tsukuba, 1-1-1 Tennodai, Tsukuba, 305-8575, Ibaraki, Japan.
Shuhei SuzukiDepartment of Urology, Institute of Medicine, University of Tsukuba, 1-1-1 Tennodai, Tsukuba, 305-8575, Ibaraki, Japan.
Kazuki HamadaDepartment of Urology, Institute of Medicine, University of Tsukuba, 1-1-1 Tennodai, Tsukuba, 305-8575, Ibaraki, Japan.
Kozaburo TanumaDepartment of Urology, Institute of Medicine, University of Tsukuba, 1-1-1 Tennodai, Tsukuba, 305-8575, Ibaraki, Japan.
Masanobu ShigaDepartment of Urology, Institute of Medicine, University of Tsukuba, 1-1-1 Tennodai, Tsukuba, 305-8575, Ibaraki, Japan.
Yoshiyuki NagumoDepartment of Urology, Institute of Medicine, University of Tsukuba, 1-1-1 Tennodai, Tsukuba, 305-8575, Ibaraki, Japan.
Hiromitsu NegoroDepartment of Urology, Institute of Medicine, University of Tsukuba, 1-1-1 Tennodai, Tsukuba, 305-8575, Ibaraki, Japan.
Bryan J MathisDepartment of Cardiovascular Surgery, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan.
Farhana FerdousiInstitute of Life and Environmental Sciences, University of Tsukuba, Tsukuba, Japan.
Hiroko IsodaInstitute of Life and Environmental Sciences, University of Tsukuba, Tsukuba, Japan.
Takashi MatsuzakaDepartment of Endocrinology and Metabolism, Institute of Medicine, University of Tsukuba, Tsukuba, Japan.
Hitoshi ShimanoDepartment of Endocrinology and Metabolism, Institute of Medicine, University of Tsukuba, Tsukuba, Japan.
Hiroyuki NishiyamaDepartment of Urology, Institute of Medicine, University of Tsukuba, 1-1-1 Tennodai, Tsukuba, 305-8575, Ibaraki, Japan.

Funding

Japan Science and Technology Agency (JST) JPMJPF2017Japan Society for the Promotion of Science 19K09664Japan Society for the Promotion of Science 22K09517
6 · The paper itself

Abstract

Clear cell renal cell carcinoma (ccRCC) frequently exhibits dysregulated lipid metabolism yet the contribution of polyunsaturated fatty acid (PUFA) elongation to malignant phenotypes remains incompletely defined. Because PUFA-elongation enzymes ELOVL2 and ELOVL5 are highly expressed in ccRCC, we investigated the clinical and functional significance of their co-overexpression. Using TCGA-KIRC data and clinical ccRCC specimens, we assessed ELOVL2/ELOVL5 expression and associations with clinicopathological features and survival. Functional studies using siRNA-mediated knockdown in renal cancer cell lines demonstrated that dual knockdown markedly suppressed proliferation, invasion, and invadopodia formation. Transcriptomic profiling and pathway analyses indicated that dual knockdown downregulated actin filament-related processes and identified LIMK1 as a candidate mediator. LIMK1 knockdown phenocopied the effects on proliferation, invasion, and invadopodia. These findings link PUFA-elongation programs to LIMK1-associated cytoskeletal remodeling in ccRCC and suggest that the ELOVL2/ELOVL5-LIMK1 axis may represent a therapeutic vulnerability.

Indexed as

AcetyltransferasesCarcinoma, Renal CellCytoskeletonFatty Acid ElongasesKidney NeoplasmsLim KinasesCell Line, TumorCell MovementCell ProliferationDisease ProgressionGene Expression Regulation, NeoplasticHumansAcetyltransferasesELOVL2 protein, humanELOVL5 protein, humanFatty Acid ElongasesLIMK1 protein, humanLim KinasesClear cell renal cell carcinomaCytoskeletal remodelingELOVL2ELOVL5LIMK1Lipid metabolism

Identifiers

PMID42225919
PMCPMC13457864

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.